A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (TAXOTERE)
Phase 1
N/A
N/A
N/A
N/A
Not Enrolling
Both
Solid Tumor Cancer
Both
Solid Tumor Cancer
Trial Information
A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (TAXOTERE)
Inclusion Criteria:
- Advanced solid tumors.
- Able to swallow oral medication.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety and Tolerability
Principal Investigator
GSK Clinical Trials, MD
Investigator Role:
Study Director
Investigator Affiliation:
GlaxoSmithKline
Authority:
United States: Food and Drug Administration
Study ID:
EGF10021
NCT ID:
NCT00148902
Start Date:
April 2003
Completion Date:
Related Keywords:
- Solid Tumor Cancer
- tumor
Name | Location |
|---|---|
| GSK Investigational Site | Germantown, Tennessee 38138 |
